Jiangsu Sinopep-Allsino Biopharmaceutical Valuation

Q: What is the Fair Price of 688076 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

688076 (CN¥52.1) is trading below our estimate of [[fair value]] (CN¥463.16)

Is 688076 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688076 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688076 (CN¥52.1) is trading below our estimate of fair value (CN¥463.16)

Significantly Below Fair Value: 688076 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688076?

Key metric: As 688076 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 688076. This is calculated by dividing 688076's market cap by their current earnings.
What is 688076's PE Ratio?
PE Ratio	27.2x
Earnings	CN¥421.47m
Market Cap	CN¥11.45b

688076 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	7.7x
Enterprise Value/EBITDA	19.4x
PEG Ratio	0.9x

Price to Earnings Ratio vs Peers

How does 688076's PE Ratio compare to its peers?

The above table shows the PE ratio for 688076 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	25.5x
300705 Hunan Jiudian Pharmaceutical	22.6x	25.5%	CN¥11.5b
300181 Zhejiang Jolly PharmaceuticalLTD	22x	23.3%	CN¥11.4b
600750 Jiang Zhong PharmaceuticalLtd	16.9x	13.1%	CN¥12.6b
300573 Shenyang Xingqi PharmaceuticalLtd	40.4x	32.8%	CN¥14.1b
688076 Jiangsu Sinopep-Allsino Biopharmaceutical	27.2x	31.4%	CN¥11.5b

Price-To-Earnings vs Peers: 688076 is expensive based on its Price-To-Earnings Ratio (27.2x) compared to the peer average (25.5x).

Price to Earnings Ratio vs Industry

How does 688076's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 688076 is good value based on its Price-To-Earnings Ratio (27.2x) compared to the CN Pharmaceuticals industry average (29.6x).

Price to Earnings Ratio vs Fair Ratio

What is 688076's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688076 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	27.2x
Fair PE Ratio	32.1x

Price-To-Earnings vs Fair Ratio: 688076 is good value based on its Price-To-Earnings Ratio (27.2x) compared to the estimated Fair Price-To-Earnings Ratio (32.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 688076 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	CN¥52.10	CN¥85.00 +63.1%	3.5%	CN¥88.00	CN¥82.00	n/a	2
Nov ’25	CN¥48.42	CN¥85.00 +75.5%	3.5%	CN¥88.00	CN¥82.00	n/a	2
Oct ’25	CN¥68.79	CN¥85.00 +23.6%	3.5%	CN¥88.00	CN¥82.00	n/a	2
Sep ’25	CN¥56.25	CN¥76.83 +36.6%	15.4%	CN¥88.00	CN¥60.49	n/a	3
Aug ’25	CN¥69.10	CN¥70.83 +2.5%	17.3%	CN¥88.00	CN¥60.49	n/a	3
Jul ’25	CN¥78.41	CN¥62.25 -20.6%	2.8%	CN¥64.00	CN¥60.49	n/a	2
Jun ’25	CN¥56.89	CN¥62.25 +9.4%	2.8%	CN¥64.00	CN¥60.49	n/a	2
May ’25	CN¥56.03	CN¥62.25 +11.1%	2.8%	CN¥64.00	CN¥60.49	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

-4.2%

-23.6%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

-3.9%

12.1%

Hunan Jiudian Pharmaceutical

CN¥11.5b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.19

-2.6%

13.6%